Zealand Pharma Stock Falls Over 11% on Obesity Drug's Side Effect Concerns

Shares of Zealand Pharma (ZELA) plunged 11.7% after its partner, Boehringer Ingelheim, released Phase III trial data for the obesity drug candidate survodutide. While the drug successfully met its primary efficacy goals, investors focused on a high patient dropout rate due to side effects, raising concerns about its commercial viability in a competitive market.

Trial Data Raises Tolerability Questions

The SYNCHRONIZE-2 trial data, presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes and published in the New England Journal of Medicine, showed that survodutide met its co-primary endpoints.

Key findings from the 76-week trial include:

• Patients achieved an average body weight reduction of up to 13.1%, compared to 3.1% for those on placebo.
• Up to 79.3% of patients treated with survodutide lost at least 5% of their body weight.

Ad

However, the data also revealed a significant tolerability issue. 18% of patients on survodutide discontinued the treatment due to gastrointestinal side effects, including nausea, vomiting, and diarrhea. This figure was substantially higher than the 1.2% discontinuation rate in the placebo group.

Market Impact and Competitive Landscape

The high dropout rate rattled investors, who are closely watching for potential differentiators in the crowded market for obesity treatments. With several effective therapies already available, a drug's tolerability profile is seen as a critical factor for patient adherence and long-term commercial success.

Zealand Pharma licensed survodutide, a glucagon/GLP-1 receptor dual agonist, to Boehringer Ingelheim. The Danish firm's future revenue from the drug is dependent on achieving development milestones and earning royalties on sales. The market's skepticism about survodutide's ability to compete translated directly into selling pressure on Zealand's shares, pushing the stock price toward its 52-week low.